Genmab — Oktober 2018
-
Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at ESMO 2018 Congress
-
-
God morgen.
-
God morgen
-
via this, but it is a pain in the neck...
https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?q=963p&r=st~19 -
Poster Display session
963P - A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
Presentation Number
963P
Lecture Time
12:30 - 12:30
Speakers
Nicole Concin (Parsippany, US)
-
Background
Treatment options for recurrent or metastatic cervical cancer are limited, with no standard of care beyond 1L treatment and 2L response rates of ∼13%. Tisotumab vedotin (TV) is an antibody-drug conjugate comprised of a fully human monoclonal antibody specific for tissue factor (TF) conjugated to the microtubule disrupting-agent monomethyl auristatin E (MMAE) via a protease cleavable linker. TV is being evaluated in GEN701 (innovaTV 201), a Phase I/IIa dose-escalation and expansion
-
study in patients (pts) with previously treated recurrent locally advanced or metastatic solid tumours. A previous report of the preliminary expansion cohort for cervical cancer (n = 34) showed an investigator (INV)-assessed response rate of 32% (26% confirmed) (Vergote et al., ESMO 2017 abstract #931O). INV response for the full cervical expansion cohort (N = 55) and response by independent imaging review (IIR) (n = 34) are presented here.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind